Compare FSLY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | RCUS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2019 | 2018 |
| Metric | FSLY | RCUS |
|---|---|---|
| Price | $33.99 | $22.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $15.67 | ★ $30.27 |
| AVG Volume (30 Days) | ★ 10.6M | 942.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,018,000.00 | $247,000,000.00 |
| Revenue This Year | $16.43 | N/A |
| Revenue Next Year | $10.45 | $70.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.78 | N/A |
| 52 Week Low | $5.13 | $7.06 |
| 52 Week High | $34.22 | $26.40 |
| Indicator | FSLY | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 69.83 | 55.73 |
| Support Level | $8.03 | $20.18 |
| Resistance Level | N/A | $24.62 |
| Average True Range (ATR) | 2.69 | 1.09 |
| MACD | 0.20 | 0.11 |
| Stochastic Oscillator | 92.95 | 83.62 |
Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.